Fortress Financial Statements From 2010 to 2025

FBIO Stock  USD 1.72  0.03  1.71%   
Fortress Biotech financial statements provide useful quarterly and yearly information to potential Fortress Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Fortress Biotech financial statements helps investors assess Fortress Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Fortress Biotech's valuation are summarized below:
Gross Profit
-85.7 M
Profit Margin
(0.49)
Market Capitalization
46.9 M
Enterprise Value Revenue
0.9758
Revenue
82.6 M
We have found one hundred twenty available fundamental signals for Fortress Biotech, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Fortress Biotech's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Enterprise Value is likely to grow to about 53.6 M, while Market Cap is likely to drop about 20.9 M.

Fortress Biotech Total Revenue

102.05 Million

Check Fortress Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fortress Biotech's main balance sheet or income statement drivers, such as Interest Expense of 14.4 M, Selling General Administrative of 120.4 M or Research Development of 128.1 M, as well as many indicators such as Price To Sales Ratio of 0.32, Dividend Yield of 0.34 or PTB Ratio of 1.18. Fortress financial statements analysis is a perfect complement when working with Fortress Biotech Valuation or Volatility modules.
  
Check out the analysis of Fortress Biotech Correlation against competitors.
To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.

Fortress Biotech Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding9.8 M9.3 M4.7 M
Slightly volatile
Total Assets173.1 M192.7 M169.5 M
Slightly volatile
Other Current Liabilities48.1 M45.8 M19.1 M
Slightly volatile
Total Current Liabilities102.5 M97.6 M52 M
Slightly volatile
Accounts Payable21 M40 M21.7 M
Slightly volatile
Cash112.2 M93.1 M107.5 M
Slightly volatile
Long Term Debt42.4 M70 M40.8 M
Slightly volatile
Other Current Assets12.7 M12.1 M6.3 M
Slightly volatile
Total Liabilities96.1 M190.8 M99.7 M
Slightly volatile
Common Stock16.4 K17.2 K151.7 K
Very volatile
Total Stockholder Equity51.5 M25.9 M45.8 M
Pretty Stable
Short and Long Term Debt Total62.1 M101.9 M56.1 M
Slightly volatile
Cash And Short Term Investments134.9 M93.1 M115.3 M
Slightly volatile
Common Stock Total Equity226.3 K116.2 K176.7 K
Pretty Stable
Liabilities And Stockholders Equity198.4 M192.7 M172.4 M
Slightly volatile
Non Current Liabilities Total57.1 M93.2 M51.7 M
Slightly volatile
Other Stockholder Equity422 M825 M394.4 M
Slightly volatile
Total Current Assets156.5 M134.6 M135.3 M
Slightly volatile
Other Liabilities2.7 M2.3 M2.3 M
Pretty Stable
Net Tangible Assets58.3 M110.5 M58.5 M
Slightly volatile
Property Plant And Equipment Net17.1 M27 M14.4 M
Slightly volatile
Non Current Assets Total45.3 M58.1 M37.4 M
Slightly volatile
Non Currrent Assets Other7.6 MM8.1 M
Pretty Stable
Net Receivables13.6 M17.7 M10.5 M
Slightly volatile
Capital Surpluse386.6 M754.4 M386.2 M
Slightly volatile
Property Plant And Equipment Gross39.1 M37.2 M15.8 M
Slightly volatile
Short Term DebtM10.9 M6.9 M
Slightly volatile
Current Deferred Revenue720.8 K758.7 K3.3 M
Pretty Stable
Long Term Debt Total99.5 M94.8 M50.5 M
Slightly volatile
Non Current Liabilities Other2.7 M2.2 M2.3 M
Pretty Stable
Short and Long Term Debt3.3 M3.5 M4.5 M
Slightly volatile
Net Invested Capital137.2 M99.4 M121.4 M
Pretty Stable
Net Working Capital27.5 M28.9 M108.9 M
Pretty Stable
Capital Stock15.4 K16.2 K462.6 K
Slightly volatile
Capital Lease Obligations18.9 M18.7 M24.1 M
Slightly volatile

Fortress Biotech Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative120.4 M114.7 M54.5 M
Slightly volatile
Research Development128.1 M122 M66 M
Slightly volatile
Depreciation And Amortization9.8 M9.3 M3.9 M
Slightly volatile
Other Operating Expenses136.5 M260.9 M133.4 M
Slightly volatile
Total Operating Expenses241.7 M230.2 M119.7 M
Slightly volatile
Non Recurring20.5 M18 M16.1 M
Slightly volatile
Interest Income1.8 M3.4 M2.3 M
Slightly volatile
Selling And Marketing Expenses91.1 M178.5 M89.3 M
Slightly volatile
Tax Provision505.9 K531.9 K941.4 K
Slightly volatile
Reconciled Depreciation6.4 M10.3 MM
Slightly volatile

Fortress Biotech Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow116.5 M95.9 M111.7 M
Slightly volatile
Stock Based Compensation12.6 M19.6 M12 M
Slightly volatile
Begin Period Cash Flow118 M208.1 M114.2 M
Slightly volatile
Depreciation7.2 M6.9 M3.3 M
Slightly volatile
Issuance Of Capital Stock92.5 M63.9 M72.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.320.3348.8559
Slightly volatile
Dividend Yield0.340.320.0835
Slightly volatile
PTB Ratio1.181.257.9552
Slightly volatile
Days Sales Outstanding12976.43144
Slightly volatile
Book Value Per Share0.210.2319.6596
Pretty Stable
Stock Based Compensation To Revenue0.220.236.4138
Slightly volatile
Capex To Depreciation0.01150.012171.4148
Slightly volatile
PB Ratio1.181.257.9552
Slightly volatile
Inventory Turnover2.853.086.2283
Pretty Stable
Days Of Inventory On Hand13212651.81
Slightly volatile
Payables Turnover0.840.881.7078
Very volatile
Sales General And Administrative To Revenue1.661.7510.3481
Slightly volatile
Research And Ddevelopement To Revenue1.371.4414.0163
Slightly volatile
Capex To Revenue8.0E-49.0E-45.3129
Slightly volatile
Cash Per Share8.538.9829.4686
Very volatile
Days Payables Outstanding475429525
Pretty Stable
Income Quality2.01.90.953
Slightly volatile
Intangibles To Total Assets0.08460.140.0606
Slightly volatile
Current Ratio1.511.585.1354
Slightly volatile
Receivables Turnover6.026.324.2192
Pretty Stable
Shareholders Equity Per Share3.043.213.0841
Slightly volatile
Debt To Equity3.653.544.1552
Pretty Stable
Capex Per Share0.00660.0071.6694
Pretty Stable
Revenue Per Share16.9511.9810.581
Slightly volatile
Interest Debt Per Share12.9111.1514.6221
Slightly volatile
Debt To Assets0.50.480.2977
Slightly volatile
Operating Cycle147186187
Very volatile
Price Book Value Ratio1.181.257.9552
Slightly volatile
Days Of Payables Outstanding475429525
Pretty Stable
Ebt Per Ebit1.131.241.0502
Slightly volatile
Company Equity Multiplier7.576.698.6529
Pretty Stable
Long Term Debt To Capitalization0.350.660.4189
Slightly volatile
Total Debt To Capitalization0.380.720.4585
Slightly volatile
Debt Equity Ratio3.653.544.1552
Pretty Stable
Quick Ratio1.371.455.0939
Slightly volatile
Net Income Per E B T0.850.450.7937
Slightly volatile
Cash Ratio1.041.14.4541
Slightly volatile
Days Of Inventory Outstanding13212651.81
Slightly volatile
Days Of Sales Outstanding12976.43144
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.241.221.175
Pretty Stable
Price To Book Ratio1.181.257.9552
Slightly volatile
Fixed Asset Turnover4.574.143.7534
Very volatile
Debt Ratio0.50.480.2977
Slightly volatile
Price Sales Ratio0.320.3348.8559
Slightly volatile
Asset Turnover0.480.450.2037
Slightly volatile
Gross Profit Margin0.440.620.4598
Slightly volatile
Price Fair Value1.181.257.9552
Slightly volatile

Fortress Biotech Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap20.9 M22 M98.8 M
Pretty Stable

Fortress Fundamental Market Drivers

Cash And Short Term Investments80.9 M

Fortress Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Fortress Biotech Financial Statements

Fortress Biotech investors utilize fundamental indicators, such as revenue or net income, to predict how Fortress Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue758.7 K720.8 K
Total Revenue97.2 M102 M
Cost Of Revenue30.7 M29.2 M
Stock Based Compensation To Revenue 0.23  0.22 
Sales General And Administrative To Revenue 1.75  1.66 
Research And Ddevelopement To Revenue 1.44  1.37 
Revenue Per Share 11.98  16.95 
Ebit Per Revenue(1.52)(1.59)

Pair Trading with Fortress Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fortress Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving together with Fortress Stock

  0.77ME 23Andme HoldingPairCorr

Moving against Fortress Stock

  0.68VALN Valneva SE ADRPairCorr
  0.58DMAC DiaMedica TherapeuticsPairCorr
  0.55VIGL Vigil NeurosciencePairCorr
  0.55DVAX Dynavax TechnologiesPairCorr
The ability to find closely correlated positions to Fortress Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fortress Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fortress Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fortress Biotech to buy it.
The correlation of Fortress Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fortress Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fortress Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fortress Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Fortress Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fortress Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fortress Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fortress Biotech Stock:
Check out the analysis of Fortress Biotech Correlation against competitors.
To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fortress Biotech. If investors know Fortress will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fortress Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(27.73)
Revenue Per Share
6.15
Quarterly Revenue Growth
(0.14)
Return On Assets
(0.36)
Return On Equity
(17.40)
The market value of Fortress Biotech is measured differently than its book value, which is the value of Fortress that is recorded on the company's balance sheet. Investors also form their own opinion of Fortress Biotech's value that differs from its market value or its book value, called intrinsic value, which is Fortress Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fortress Biotech's market value can be influenced by many factors that don't directly affect Fortress Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.